好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Daclizumab Inhibits Expansion of Antigen (Ag)-Specific T Cells by Blocking IL-2 Transpresentation by Dendritic Cells
MS and Related Diseases
(-)
217
Authors/Disclosures
No disclosure on file
No disclosure on file
Sungpil Han (NINDS NIH) No disclosure on file
April A. Erwin, MD (Rocky Mountain Multiple Sclerosis Clinic) Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Celgene. Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Erwin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Erwin has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol-Myers Squibb. The institution of Dr. Erwin has received research support from Genentech. The institution of Dr. Erwin has received research support from Abbvie. The institution of Dr. Erwin has received research support from Novartis. The institution of Dr. Erwin has received research support from Biogen.
No disclosure on file
No disclosure on file
Bibiana Bielekova, MD, FAAN (Neuroimmunological Diseases Section/NIAID/NIH) Dr. Bielekova has received research support from National Institutes of Allergy and Infectious Diseases. Dr. Bielekova has received intellectual property interests from a discovery or technology relating to health care. Dr. Bielekova has received publishing royalties from a publication relating to health care.